Antimicrob Agents Chemother. 2010 Nov;54(11):4903-6. Epub 2010 Aug 30.

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Young TP, Parkin NT, Stawiski E, Pilot-Matias T, Trinh R, Kempf DJ, Norton M.

Source

Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018-3315, USA. tom.young@abbott.com

Abstract

Patterns of HIV-1 protease inhibitor (PI) resistance-associated mutations (RAMs) and effects on PI susceptibility associated with the L76V mutation were studied in a large database. Of 20,501 sequences with ≥1 PI RAM, 3.2% contained L76V; L76V was alone in 0.04%. Common partner mutations included M46I, I54V, V82A, I84V, and L90M. L76V was associated with a 2- to 6-fold decrease in susceptibility to lopinavir, darunavir, amprenavir, and indinavir and a 7- to 8-fold increase in susceptibility to atazanavir and saquinavir.

PMID:: 20805393; [PubMed - indexed for MEDLINE]
PMCID: PMC2976162

Free PMC Article

Images from this publication.See all images (2) Free text

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Molecular Biology Databases

AMPRENAVIR - HSDB

Supplemental Content

Related citations

HIV-1 protease mutations and protease inhibitor cross-resistance. [Antimicrob Agents Chemother. 2010]
HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, et al. Antimicrob Agents Chemother. 2010 Oct; 54(10):4253-61. Epub 2010 Jul 26.
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. [AIDS Res Hum Retroviruses. 2002]
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D, Liao Q, Fusco G, St Clair M, Shaefer M, Ross L. AIDS Res Hum Retroviruses. 2002 Sep 20; 18(14):1011-9.
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. [AIDS. 2002]
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J. AIDS. 2002 May 3; 16(7):1009-17.
Review Darunavir: a review of its use in the management of HIV infection in adults. [Drugs. 2009]
Review Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K, Perry CM, Keam SJ. Drugs. 2009; 69(4):477-503.
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. [Antivir Ther. 2004]
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D, Schapiro JM, Brenner BG, Wainberg MA. Antivir Ther. 2004 Jun; 9(3):301-14.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
BioAssay
PubChem BioAssay experiments on the biological activities of small molecules that cite the current articles. The depositors of BioAssay data provide these references.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility ...
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Antimicrob Agents Chemother. 2010 Nov ;54(11):4903-6. Epub 2010 Aug 30 .

PubMed
Perspectives on poststroke sexual issues and rehabilitation needs.
Perspectives on poststroke sexual issues and rehabilitation needs.
Top Stroke Rehabil. 2010 May-Jun ;17(3):204-13.

PubMed
32nd National Medicinal Chemistry Symposium--medicinal chemistry developments fo...
32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for neurodegeneration, diabetes and cancer.
IDrugs. 2010 Aug ;13(8):514-6.

PubMed
Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens...
Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro.
Toxicol Lett. 2010 Oct 5 ;198(2):272-81. Epub 2010 Jul 22 .

PubMed
The discovery of an orally efficacious positive allosteric modulator of the calc...
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.
Bioorg Med Chem Lett. 2010 Sep 15 ;20(18):5544-7. Epub 2010 Aug 12 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Supplemental Content

Related citations

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information